{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008118","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.886860+00:00","generated_at":"2026-06-15T22:16:48.413075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure reports Q1 net loss $16.1M, cash $145.5M; pipeline data expected Q4 2023","bullets":["Net loss $16.1M for Q1 2023 vs $20.6M loss in Q1 2022, narrowing on lower R&D expenses.","Cash $145.5M down from $159.9M; expects runway into mid-2025.","Three clinical programs (NC410, NC762, NC525) data updates expected in Q4 2023.","First patient dosed with NC525 (LAIR-1 mAb) Phase 1 in AML in Feb 2023.","R&D expenses decreased to $11.6M from $15.0M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008118","json":"https://secwatch.observer/filing/0001558370-23-008118.json","markdown":"https://secwatch.observer/filing/0001558370-23-008118.md","text":"https://secwatch.observer/filing/0001558370-23-008118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/0001558370-23-008118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/nxtc-20230504x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:16:48.413075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6c51176db9caa45d2cf999db3a220e84022f781","claim":"NextCure, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported first quarter 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023008118/0001558370-23-008118-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}